Int J Stroke:中国伴发心房颤动的卒中患者中口服抗凝药使用率偏低(ChinaQUEST注册研究)

2014-10-04 MedSci MedSci原创

国际指南建议房颤患者根据个人发生卒中的风险而使用口服抗凝药物。这项研究的目的是确定近期患缺血性卒中的房颤患者中,口服抗凝药物的使用情况,并探究在中国影响这种治疗的相关因素。在一项多中心、前瞻性、62所注册医院参与的“中国卒中医疗质量评估”( (Quality Evaluation of Stroke Care and Treatment))中记录的急性缺血性卒中患者中(n =4782

国际指南建议房颤患者根据个人发生卒中的风险而使用口服抗凝药物。这项研究的目的是确定近期患缺血性卒中的房颤患者中,口服抗凝药物的使用情况,并探究在中国影响这种治疗的相关因素。

在一项多中心、前瞻性、62所注册医院参与的“中国卒中医疗质量评估”( (Quality Evaluation of Stroke Care and Treatment))中记录的急性缺血性卒中患者中(n =4782),有499名患者(10%)(平均年龄70±12岁,女性占49%)患有房颤,并具有超过12个月的随访记录。我们用Logistic回归分析来确定在这些患者中使用口服抗凝药物的独立预测因子。

结果发现,499名伴发房颤的卒中患者中,口服抗凝药物的总体平均使用率为20%;口服抗凝药物的使用比例在卒中前、卒中后住院时、卒中后3个月、卒中后12个月分别为8%、11%、13%和10%不等。低龄(比值比0.95,95%可信区间为0.93-0.97,P<0.001)、非体力劳动职业(比值比0.44,95%的置信区间为0.25-0.80,P=0.006)、较少的心血管疾病危险因素(比值比0.81,95%可信区间为0.68-0.96,P=0.02)与口服抗凝药物使用独立相关。

这些数据表明,跟西方国家对比,中国伴发房颤的卒中患者使用口服抗凝药物的比例偏低,抗凝药物较多使用于年轻、非体力劳动的职业、并具有较少心血管疾病危险因素的患者。

MedSci注:ChinaQUEST登记数据库从2009年以来,一共发表了11篇较高质量的SCI文章,未来这个数据库还能挖掘出巨大的临床研究资源,会源源不断产生高质量的研究论文。从这里也可以看出登记数据库的价值。

原始出处:
Heeley EL, Wei JW, Wang JG, Arima H, Huang Y, Wong LK, Anderson CS; ChinaQUESTInvestigators.Comparative effects of antihypertensive drugs on stroke outcome in China. Int J Stroke. 2014 Jul 15. doi: 10.1111/ijs.12330

ChinaQUEST登记数据库发表的其它研究论文:

Jin H, Zhu S, Wei JW, Wang J, Liu M, Wu Y, Wong LK, Cheng Y, Xu E, Yang Q, Anderson CS, Huang Y; ChinaQUEST (Quality Evaluation of Stroke Care and Treatment) Investigators.Factors associated with prehospital delays in the presentation of acute stroke in urban China. Stroke. 2012 Feb;43(2):362-70. 

Gao Q, Fu X, Wei JW, Chen X, Huang Y, Wang J, Anderson CS, Wong KS; China QUEST Study Investigators.Use of oral anticoagulation among stroke patients with atrial fibrillation in China: the ChinaQUEST(Quality evaluation of stroke care and treatment) registry study. Int J Stroke. 2013 Apr;8(3):150-4

Wei JW, Huang Y, Wang JG, Liu M, Wong LK, Huang Q, Wu L, Heeley EL, Arima H, Anderson CS;ChinaQUEST Investigators.Current management of intracerebral haemorrhage in China: a national, multi-centre, hospital register study. BMC Neurol. 2011 Jan 30;11:16.

Delcourt C, Hackett M, Wu Y, Huang Y, Wang J, Heeley E, Wong L, Sun J, Li Q, Wei JW, Liu M, Li Z, Wu L, Cheng Y, Huang Q, Xu E, Yang Q, Lu C, Anderson CS; ChinaQUEST Investigators.Determinants of quality of life after stroke in China: the ChinaQUEST (QUality Evaluation of Stroke care and Treatment) study. Stroke. 2011 Feb;42(2):433-8. 

Wei JW, Heeley EL, Jan S, Huang Y, Huang Q, Wang JG, Cheng Y, Xu E, Yang Q, Anderson CS;ChinaQUEST Investigators.Variations and determinants of hospital costs for acute stroke in China. PLoS One. 2010 Sep 28;5(9). pii: e13041.

Huang Y, Wang JG, Wei JW, Headley AP, Wong LK, Heeley EL, Arima H, Sun J, Li Q, Liu M, Li Z, Wu L, Cheng Y, Huang Q, Zhang S, Xu E, Yang Q, Lu C, Anderson CS; ChinaQUEST Investigators.Age and gender variations in the management of ischaemic stroke in China. Int J Stroke. 2010 Oct;5(5):351-9.

Wei JW, Heeley EL, Wang JG, Huang Y, Wong LK, Li Z, Heritier S, Arima H, Anderson CS;ChinaQUEST Investigators.Comparison of recovery patterns and prognostic indicators for ischemic and hemorrhagic stroke in China: the ChinaQUEST (QUality Evaluation of Stroke Care and Treatment) Registry study. Stroke. 2010 Sep;41(9):1877-83

Wei JW, Wang JG, Huang Y, Liu M, Wu Y, Wong LK, Cheng Y, Xu E, Yang Q, Arima H, Heeley EL, Anderson CS; ChinaQUEST Investigators.Secondary prevention of ischemic stroke in urban China. Stroke. 2010 May;41(5):967-74

Wei JW, Arima H, Huang Y, Wang JG, Yang Q, Liu Z, Liu M, Lu C, Heeley EL, Anderson CS;ChinaQUEST Investigators.Variation in the frequency of intracerebral haemorrhage and ischaemic stroke in China: a national, multicentre, hospital register study. Cerebrovasc Dis. 2010;29(4):321-7.

Heeley E, Anderson CS, Huang Y, Jan S, Li Y, Liu M, Sun J, Xu E, Wu Y, Yang Q, Zhang J, Zhang S, Wang J; ChinaQUEST Investigators.Role of health insurance in averting economic hardship in families after acute stroke in China. Stroke. 2009 Jun;40(6):2149-56

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2008100, encodeId=67ca200810076, content=<a href='/topic/show?id=f244465139' target=_blank style='color:#2F92EE;'>#CHINA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4651, encryptionId=f244465139, topicName=CHINA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Jul 02 06:55:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720030, encodeId=57181e2003018, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Fri Oct 17 21:55:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050415, encodeId=f140205041501, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Aug 16 05:55:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764749, encodeId=3ea51e64749c1, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Wed Aug 19 17:55:00 CST 2015, time=2015-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783207, encodeId=d2151e8320749, content=<a href='/topic/show?id=ece04653cc' target=_blank style='color:#2F92EE;'>#ChinaQUEST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4653, encryptionId=ece04653cc, topicName=ChinaQUEST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Wed Nov 05 17:55:00 CST 2014, time=2014-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377354, encodeId=94b113e73545e, content=<a href='/topic/show?id=3098382134a' target=_blank style='color:#2F92EE;'>#口服抗凝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38213, encryptionId=3098382134a, topicName=口服抗凝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556711, encodeId=626d1556e114e, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615898, encodeId=3de3161589837, content=<a href='/topic/show?id=158826812c4' target=_blank style='color:#2F92EE;'>#使用率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26812, encryptionId=158826812c4, topicName=使用率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dee19693687, createdName=ms3830150583600765, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626797, encodeId=f1361626e97bf, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11965, encodeId=731a119652e, content=这么多文章呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=42.122.187.59, createdTime=Sun Oct 05 08:20:00 CST 2014, time=2014-10-05, status=1, ipAttribution=)]
    2015-07-02 drwjr
  2. [GetPortalCommentsPageByObjectIdResponse(id=2008100, encodeId=67ca200810076, content=<a href='/topic/show?id=f244465139' target=_blank style='color:#2F92EE;'>#CHINA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4651, encryptionId=f244465139, topicName=CHINA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Jul 02 06:55:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720030, encodeId=57181e2003018, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Fri Oct 17 21:55:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050415, encodeId=f140205041501, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Aug 16 05:55:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764749, encodeId=3ea51e64749c1, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Wed Aug 19 17:55:00 CST 2015, time=2015-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783207, encodeId=d2151e8320749, content=<a href='/topic/show?id=ece04653cc' target=_blank style='color:#2F92EE;'>#ChinaQUEST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4653, encryptionId=ece04653cc, topicName=ChinaQUEST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Wed Nov 05 17:55:00 CST 2014, time=2014-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377354, encodeId=94b113e73545e, content=<a href='/topic/show?id=3098382134a' target=_blank style='color:#2F92EE;'>#口服抗凝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38213, encryptionId=3098382134a, topicName=口服抗凝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556711, encodeId=626d1556e114e, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615898, encodeId=3de3161589837, content=<a href='/topic/show?id=158826812c4' target=_blank style='color:#2F92EE;'>#使用率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26812, encryptionId=158826812c4, topicName=使用率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dee19693687, createdName=ms3830150583600765, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626797, encodeId=f1361626e97bf, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11965, encodeId=731a119652e, content=这么多文章呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=42.122.187.59, createdTime=Sun Oct 05 08:20:00 CST 2014, time=2014-10-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2008100, encodeId=67ca200810076, content=<a href='/topic/show?id=f244465139' target=_blank style='color:#2F92EE;'>#CHINA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4651, encryptionId=f244465139, topicName=CHINA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Jul 02 06:55:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720030, encodeId=57181e2003018, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Fri Oct 17 21:55:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050415, encodeId=f140205041501, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Aug 16 05:55:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764749, encodeId=3ea51e64749c1, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Wed Aug 19 17:55:00 CST 2015, time=2015-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783207, encodeId=d2151e8320749, content=<a href='/topic/show?id=ece04653cc' target=_blank style='color:#2F92EE;'>#ChinaQUEST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4653, encryptionId=ece04653cc, topicName=ChinaQUEST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Wed Nov 05 17:55:00 CST 2014, time=2014-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377354, encodeId=94b113e73545e, content=<a href='/topic/show?id=3098382134a' target=_blank style='color:#2F92EE;'>#口服抗凝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38213, encryptionId=3098382134a, topicName=口服抗凝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556711, encodeId=626d1556e114e, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615898, encodeId=3de3161589837, content=<a href='/topic/show?id=158826812c4' target=_blank style='color:#2F92EE;'>#使用率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26812, encryptionId=158826812c4, topicName=使用率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dee19693687, createdName=ms3830150583600765, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626797, encodeId=f1361626e97bf, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11965, encodeId=731a119652e, content=这么多文章呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=42.122.187.59, createdTime=Sun Oct 05 08:20:00 CST 2014, time=2014-10-05, status=1, ipAttribution=)]
    2015-08-16 heli0118
  4. [GetPortalCommentsPageByObjectIdResponse(id=2008100, encodeId=67ca200810076, content=<a href='/topic/show?id=f244465139' target=_blank style='color:#2F92EE;'>#CHINA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4651, encryptionId=f244465139, topicName=CHINA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Jul 02 06:55:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720030, encodeId=57181e2003018, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Fri Oct 17 21:55:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050415, encodeId=f140205041501, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Aug 16 05:55:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764749, encodeId=3ea51e64749c1, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Wed Aug 19 17:55:00 CST 2015, time=2015-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783207, encodeId=d2151e8320749, content=<a href='/topic/show?id=ece04653cc' target=_blank style='color:#2F92EE;'>#ChinaQUEST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4653, encryptionId=ece04653cc, topicName=ChinaQUEST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Wed Nov 05 17:55:00 CST 2014, time=2014-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377354, encodeId=94b113e73545e, content=<a href='/topic/show?id=3098382134a' target=_blank style='color:#2F92EE;'>#口服抗凝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38213, encryptionId=3098382134a, topicName=口服抗凝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556711, encodeId=626d1556e114e, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615898, encodeId=3de3161589837, content=<a href='/topic/show?id=158826812c4' target=_blank style='color:#2F92EE;'>#使用率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26812, encryptionId=158826812c4, topicName=使用率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dee19693687, createdName=ms3830150583600765, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626797, encodeId=f1361626e97bf, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11965, encodeId=731a119652e, content=这么多文章呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=42.122.187.59, createdTime=Sun Oct 05 08:20:00 CST 2014, time=2014-10-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2008100, encodeId=67ca200810076, content=<a href='/topic/show?id=f244465139' target=_blank style='color:#2F92EE;'>#CHINA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4651, encryptionId=f244465139, topicName=CHINA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Jul 02 06:55:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720030, encodeId=57181e2003018, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Fri Oct 17 21:55:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050415, encodeId=f140205041501, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Aug 16 05:55:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764749, encodeId=3ea51e64749c1, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Wed Aug 19 17:55:00 CST 2015, time=2015-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783207, encodeId=d2151e8320749, content=<a href='/topic/show?id=ece04653cc' target=_blank style='color:#2F92EE;'>#ChinaQUEST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4653, encryptionId=ece04653cc, topicName=ChinaQUEST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Wed Nov 05 17:55:00 CST 2014, time=2014-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377354, encodeId=94b113e73545e, content=<a href='/topic/show?id=3098382134a' target=_blank style='color:#2F92EE;'>#口服抗凝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38213, encryptionId=3098382134a, topicName=口服抗凝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556711, encodeId=626d1556e114e, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615898, encodeId=3de3161589837, content=<a href='/topic/show?id=158826812c4' target=_blank style='color:#2F92EE;'>#使用率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26812, encryptionId=158826812c4, topicName=使用率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dee19693687, createdName=ms3830150583600765, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626797, encodeId=f1361626e97bf, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11965, encodeId=731a119652e, content=这么多文章呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=42.122.187.59, createdTime=Sun Oct 05 08:20:00 CST 2014, time=2014-10-05, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2008100, encodeId=67ca200810076, content=<a href='/topic/show?id=f244465139' target=_blank style='color:#2F92EE;'>#CHINA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4651, encryptionId=f244465139, topicName=CHINA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Jul 02 06:55:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720030, encodeId=57181e2003018, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Fri Oct 17 21:55:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050415, encodeId=f140205041501, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Aug 16 05:55:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764749, encodeId=3ea51e64749c1, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Wed Aug 19 17:55:00 CST 2015, time=2015-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783207, encodeId=d2151e8320749, content=<a href='/topic/show?id=ece04653cc' target=_blank style='color:#2F92EE;'>#ChinaQUEST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4653, encryptionId=ece04653cc, topicName=ChinaQUEST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Wed Nov 05 17:55:00 CST 2014, time=2014-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377354, encodeId=94b113e73545e, content=<a href='/topic/show?id=3098382134a' target=_blank style='color:#2F92EE;'>#口服抗凝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38213, encryptionId=3098382134a, topicName=口服抗凝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556711, encodeId=626d1556e114e, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615898, encodeId=3de3161589837, content=<a href='/topic/show?id=158826812c4' target=_blank style='color:#2F92EE;'>#使用率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26812, encryptionId=158826812c4, topicName=使用率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dee19693687, createdName=ms3830150583600765, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626797, encodeId=f1361626e97bf, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11965, encodeId=731a119652e, content=这么多文章呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=42.122.187.59, createdTime=Sun Oct 05 08:20:00 CST 2014, time=2014-10-05, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2008100, encodeId=67ca200810076, content=<a href='/topic/show?id=f244465139' target=_blank style='color:#2F92EE;'>#CHINA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4651, encryptionId=f244465139, topicName=CHINA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Jul 02 06:55:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720030, encodeId=57181e2003018, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Fri Oct 17 21:55:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050415, encodeId=f140205041501, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Aug 16 05:55:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764749, encodeId=3ea51e64749c1, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Wed Aug 19 17:55:00 CST 2015, time=2015-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783207, encodeId=d2151e8320749, content=<a href='/topic/show?id=ece04653cc' target=_blank style='color:#2F92EE;'>#ChinaQUEST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4653, encryptionId=ece04653cc, topicName=ChinaQUEST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Wed Nov 05 17:55:00 CST 2014, time=2014-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377354, encodeId=94b113e73545e, content=<a href='/topic/show?id=3098382134a' target=_blank style='color:#2F92EE;'>#口服抗凝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38213, encryptionId=3098382134a, topicName=口服抗凝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556711, encodeId=626d1556e114e, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615898, encodeId=3de3161589837, content=<a href='/topic/show?id=158826812c4' target=_blank style='color:#2F92EE;'>#使用率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26812, encryptionId=158826812c4, topicName=使用率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dee19693687, createdName=ms3830150583600765, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626797, encodeId=f1361626e97bf, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11965, encodeId=731a119652e, content=这么多文章呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=42.122.187.59, createdTime=Sun Oct 05 08:20:00 CST 2014, time=2014-10-05, status=1, ipAttribution=)]
    2014-10-06 zhyy93
  8. [GetPortalCommentsPageByObjectIdResponse(id=2008100, encodeId=67ca200810076, content=<a href='/topic/show?id=f244465139' target=_blank style='color:#2F92EE;'>#CHINA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4651, encryptionId=f244465139, topicName=CHINA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Jul 02 06:55:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720030, encodeId=57181e2003018, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Fri Oct 17 21:55:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050415, encodeId=f140205041501, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Aug 16 05:55:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764749, encodeId=3ea51e64749c1, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Wed Aug 19 17:55:00 CST 2015, time=2015-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783207, encodeId=d2151e8320749, content=<a href='/topic/show?id=ece04653cc' target=_blank style='color:#2F92EE;'>#ChinaQUEST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4653, encryptionId=ece04653cc, topicName=ChinaQUEST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Wed Nov 05 17:55:00 CST 2014, time=2014-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377354, encodeId=94b113e73545e, content=<a href='/topic/show?id=3098382134a' target=_blank style='color:#2F92EE;'>#口服抗凝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38213, encryptionId=3098382134a, topicName=口服抗凝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556711, encodeId=626d1556e114e, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615898, encodeId=3de3161589837, content=<a href='/topic/show?id=158826812c4' target=_blank style='color:#2F92EE;'>#使用率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26812, encryptionId=158826812c4, topicName=使用率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dee19693687, createdName=ms3830150583600765, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626797, encodeId=f1361626e97bf, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11965, encodeId=731a119652e, content=这么多文章呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=42.122.187.59, createdTime=Sun Oct 05 08:20:00 CST 2014, time=2014-10-05, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=2008100, encodeId=67ca200810076, content=<a href='/topic/show?id=f244465139' target=_blank style='color:#2F92EE;'>#CHINA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4651, encryptionId=f244465139, topicName=CHINA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Jul 02 06:55:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720030, encodeId=57181e2003018, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Fri Oct 17 21:55:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050415, encodeId=f140205041501, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Aug 16 05:55:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764749, encodeId=3ea51e64749c1, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Wed Aug 19 17:55:00 CST 2015, time=2015-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783207, encodeId=d2151e8320749, content=<a href='/topic/show?id=ece04653cc' target=_blank style='color:#2F92EE;'>#ChinaQUEST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4653, encryptionId=ece04653cc, topicName=ChinaQUEST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Wed Nov 05 17:55:00 CST 2014, time=2014-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377354, encodeId=94b113e73545e, content=<a href='/topic/show?id=3098382134a' target=_blank style='color:#2F92EE;'>#口服抗凝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38213, encryptionId=3098382134a, topicName=口服抗凝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556711, encodeId=626d1556e114e, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615898, encodeId=3de3161589837, content=<a href='/topic/show?id=158826812c4' target=_blank style='color:#2F92EE;'>#使用率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26812, encryptionId=158826812c4, topicName=使用率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dee19693687, createdName=ms3830150583600765, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626797, encodeId=f1361626e97bf, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11965, encodeId=731a119652e, content=这么多文章呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=42.122.187.59, createdTime=Sun Oct 05 08:20:00 CST 2014, time=2014-10-05, status=1, ipAttribution=)]
    2014-10-06 sodoo
  10. [GetPortalCommentsPageByObjectIdResponse(id=2008100, encodeId=67ca200810076, content=<a href='/topic/show?id=f244465139' target=_blank style='color:#2F92EE;'>#CHINA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4651, encryptionId=f244465139, topicName=CHINA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Jul 02 06:55:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720030, encodeId=57181e2003018, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Fri Oct 17 21:55:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050415, encodeId=f140205041501, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Aug 16 05:55:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764749, encodeId=3ea51e64749c1, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Wed Aug 19 17:55:00 CST 2015, time=2015-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783207, encodeId=d2151e8320749, content=<a href='/topic/show?id=ece04653cc' target=_blank style='color:#2F92EE;'>#ChinaQUEST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4653, encryptionId=ece04653cc, topicName=ChinaQUEST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Wed Nov 05 17:55:00 CST 2014, time=2014-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377354, encodeId=94b113e73545e, content=<a href='/topic/show?id=3098382134a' target=_blank style='color:#2F92EE;'>#口服抗凝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38213, encryptionId=3098382134a, topicName=口服抗凝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556711, encodeId=626d1556e114e, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615898, encodeId=3de3161589837, content=<a href='/topic/show?id=158826812c4' target=_blank style='color:#2F92EE;'>#使用率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26812, encryptionId=158826812c4, topicName=使用率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dee19693687, createdName=ms3830150583600765, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626797, encodeId=f1361626e97bf, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Mon Oct 06 14:55:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11965, encodeId=731a119652e, content=这么多文章呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=42.122.187.59, createdTime=Sun Oct 05 08:20:00 CST 2014, time=2014-10-05, status=1, ipAttribution=)]
    2014-10-05 42.122.187.59

    这么多文章呀

    0

相关资讯

杨杰孚:房颤抗凝治疗研究进展,从指南更新到真实世界实践检验

——从指南更新到真实世界实践检验 北京医院 杨杰孚 2014年3月29日至31日,一年一度的美国心脏病学会(ACC)年会在美国华盛顿召开。在本届ACC年会上,房颤抗凝领域的一大学术热点是2014美国心脏学会(AHA)/ACC/美国心律学会(HRS)房颤患者管理指南最新版的公布。这是继2014年美国神经病学会(AAN)非瓣膜性房颤(NVAF)患者卒中预防指南之后房颤领域的又一

Am J Cardiol:强化降糖不影响2型糖尿病患者新发房颤率(ACCORD试验)

心房颤动(AF)在2型糖尿病患者中较为常见,且与血糖控制不佳的标志物相关,但血糖对AF的影响和转归尚未知。美国学者对此进行了一项前瞻性研究,结果表明,强化血糖控制不影响新发房颤率;与那些无AF者相比,合并房颤的糖尿病患者发病和死亡风险均增加。论文8月1日美国心脏病学杂志(American Journal of Cardiology)。 该研究共纳入10082例糖尿病患者,他们被随机分为强

JAMA:延迟纠正房颤的不规则心律与并发症风险增加有关

据8月13日发表在《美国医学会杂志》中的一项研究披露,延迟纠正因为房颤的一种异常心律达12小时或更长时间与发生诸如中风等血栓栓塞性并发症的较大风险有关。 在1995年,治疗实践指南建议在房颤(AF)发作后不用抗凝药进行心脏复律(将异常心律转化为正常心律)的时间极限为48小时。根据文章的背景资讯,当在不到48小时内不用抗凝药进行心脏复律时,人们不知道出现血栓栓塞性并发症的风险是否会增加。

从Protect-AF研究看左心耳封堵术用于房颤患者血栓栓塞的未来

左心耳封堵术(Left Atrial Appendage ocllusion,LAAO)是近年来发展的通过微创导管术封堵左心耳、以达到预防心房颤动(房颤)患者血栓栓塞的新技术。Protect-AF研究是关于LAAO的第一个随机对照研究,和既往的研究有很大不同:首先是既往研究都是非对照研究,和该研究是对比LAAO和华法林治疗的随机对照研究;其次,既往的研究入选的是抗凝禁忌或者是抗凝风险高的患者,

Circulation:FGF23或许是连接房颤与慢性肾脏病的桥梁

慢性肾脏病(CKD)患者往往属于心血管疾病高危患者。成纤维细胞生长因子 23(FGF23)促进肾脏磷分泌和维生素 D 代谢,慢性肾脏病患者 FGF23 水平升高,另外,FGF23 升高增加包括房颤在内的心血管疾病风险增加。那么,FGF23 是否是连接房颤和 CKD 的桥梁?最近一项发表在 Circulation 上的研究或许支持此种联系。研究牵头人 Jehu Mathew 博士解释道:“我们试图研

ESC 2014:利伐沙班可促房颤患者心脏复律

ESC 2014公布的一项研究表明,在房颤患者中,口服利伐沙班可安全有效的替代维生素K拮抗剂(VKA),并且可促进心脏复律。论文于9月4日在线发表于《欧洲心脏杂志》(Eur Heart J)。 此项研究共纳入1504例房颤患者,并以2:1比率随机给予利伐沙班或VKA治疗。早期和延迟心脏复律策略由研究者选定。主要有效性复合转归由卒中、短暂性脑缺血发作、外周动脉栓塞、心肌梗死和心血管死亡所组成,